Apellis Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
Apellis Pharmaceuticals stock last closed at $18.03, down 0.93% from the previous day, and has decreased 62.15% in one year. It has overperformed other stocks in the Biotechnology industry by 0.15 percentage points. Apellis Pharmaceuticals stock is currently +3.12% from its 52-week low of $17.49, and -64.63% from its 52-week high of $50.98.
As of Apr 21, 2025, there are 125.52M shares of APLS outstanding. The market cap of APLS is $2.26B. In the last 24 hours, 1.79M APLS shares were traded.
How to Buy Apellis Pharmaceuticals Stock
Wondering how to invest in Apellis Pharmaceuticals stock? Here's how.
Decide where to buy Apellis Pharmaceuticals stock: You need to pick an online brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you decide where to buy Apellis Pharmaceuticals stock.
Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
Deposit money your investment account: Choose your method of payment and add your info.
Analyze Apellis Pharmaceuticals stock: The Apellis Pharmaceuticals ticker symbol is APLS. Is Apellis Pharmaceuticals stock a good investment? Should you buy shares of APLS? How do APLS's underlying business fundamentals look? Do top analysts think Apellis Pharmaceuticals is a good buy? Why has APLS's stock price moved recently? (Hint: Our stock analysis website can help you understand if APLS is a good stock to buy).
Execute your APLS trade: Decide if you will purchase APLS shares at the current market price or use a limit order to buy APLS shares at a specific price.
Keep tabs on your APLS position: Create a watchlist to the latest updates on your investment in Apellis Pharmaceuticals shares.
Step 1: Decide where to buy Apellis Pharmaceuticals stock
You need a brokerage account in order to access the NASDAQ market and buy APLS stock.
A brokerage account allows you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
We believe that eToro is the best brokerage. Here's why:
Invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
Access to world financial markets: From Technology to Healthcare, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for a brokerage account
Now that you've selected the right brokerage, you'll need to fill out some personal info so you can buy APLS stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Apellis Pharmaceuticals stock
After you have decided on the best place to buy Apellis Pharmaceuticals stock, it's crucial to evaluate their stock prior to buying, so you can wrap your head around the risk and opportunity.
Overview of key APLS info
APLS Price
$18.03
1w %
-6.73%
1y %
-62.15%
5y %
-48.28%
P/E
-11.27x
P/B
9.9x
P/S
2.86x
PEG
N/A
Revenue
$781.37M
Earnings
-$197.88M
Fore. Rev. Growth
16.22%
Fore. Earn. Growth
N/A
Market Cap
$2.26B
Next Earnings
May 5, 2025
Next Dividend
N/A
APLS Fundamentals
WallStreetZen was created to help part-time investors do more in-depth fundamental analysis quickly.
There are more short-term assets than long-term liabilities on the APLS balance sheet.
Total APLS debt is lower than 5 years ago, relative to shareholder equity.
APLS has $412.61M in cash and short term investments. This is enough to cover its annual cash burn of $88.27M.
There are more short-term assets than short-term liabilities on the APLS balance sheet.
APLS has cash burn of 88269000. It has enough cash and short-term investments to cover this for at least one year.
Failed Health Checks:
APLS profit margin has gone up by 1.08 percentage points in the past year, but the company is still unprofitable.
APLS has a relatively high debt to equity ratio of 2.87.
Is it a good time to buy APLS stock, according to analysts?
Out of 15 sell side analysts who give ratings on APLS, the consensus analyst rating on APLS is a Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Most Recent APLS Analyst Ratings
Douglas Tsao, a bottom 1% analyst from HC Wainwright & Co. reiterates APLS with a buy rating and maintains their APLS price target from $57.00 to $57.00, on Mar 3, 2025.
Judah Frommer, a bottom 9% analyst from Morgan Stanley initiates coverage on APLS with a hold rating and announces their APLS price target of $31.00, on Nov 21, 2024.
Colleen Kusy, a bottom 8% analyst from Baird maintains APLS with a buy rating and lowers their APLS price target from $92.00 to $55.00, on Nov 7, 2024.
Yigal Nochomovitz, a top 15% analyst from Citigroup maintains APLS with a strong buy rating and lowers their APLS price target from $63.00 to $51.00, on Nov 6, 2024.
Derek Archila, a top 2% analyst from Wells Fargo maintains APLS with a hold rating and lowers their APLS price target from $43.00 to $30.00, on Nov 6, 2024.
Last year, APLS revenue was $781.37M. In the last 4 year, APLS's revenue has gone up by 32.88% per year. This was slower than the Biotechnology industry average of 44.31%.
No, Apellis Pharmaceuticals doesn't provide an income stream by paying out dividends.
What do other investors have to say about APLS?
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your APLS trade
There are two primary order types:
Market order: A market order is an order to buy or sell a stock at the best possible price. Market orders are usually sufficient.
Limit order: A limit order enables you to buy or sell a security at a specific price (or better). If you want to make sure you're buying or selling at a particular dollar amount, place a limit order.
Click the Open button and eToro will execute your order.
If you need more help buying stocks on eToro, click the helpful video below:
How much does it cost to buy one Apellis Pharmaceuticals share?
As of Apr 21, 2025, it costs $18.03 to buy one share of Apellis Pharmaceuticals stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $9, you can buy 0.499 shares of APLS.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.